Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director Kimberly H. Johnson acquired 10 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Summary

• Kimberly H. Johnson, a director at Eli Lilly & Co, acquired 10 shares of common stock on September 16, 2024.
• The shares were acquired at a price of $923.54 per share.
• These shares were obtained through the Lilly Directors' Deferral Plan, in lieu of cash compensation.
• The shares will be settled in common stock following Ms. Johnson's separation from service.
• Following this transaction, Ms. Johnson directly owns 2,688 shares of Eli Lilly common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, indicating a neutral to slightly positive sentiment due to director's increased stake in the company.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.
• The use of a deferral plan aligns director compensation with long-term company performance.

Future Outlook

The acquired shares will be settled in common stock following the director's separation from service.

Industry Context

This is a routine filing related to director compensation and stock ownership, which is common in publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among large publicly traded companies like Eli Lilly.
• Many pharmaceutical companies such as Pfizer and Merck also utilize similar compensation structures for their directors.
• The price of $923.54 per share is consistent with the market valuation of Eli Lilly stock at the time of the transaction.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with company performance.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, SEC Form 4, Stock Ownership, Kimberly H. Johnson